Skip to main content
Explore URMC

Patrick M. Reagan, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Fax: (585) 273-5761

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Hospital Medicine


I am a clinician and researcher specializing in the care of patients with both Non Hodgkin and Hodgkin lymphomas. Areas of particular interest include aggressive B-cell lymphomas such as diffuse large B-cell lymphoma and "double hit" lymphoma, autologous stem cell transplantation and cellular therapy including chimeric antigen receptor (CAR) T-cells.

Lymphomas are a complex group of diseases and require a multidisciplinary team to manage. We are fortunate to have an excellent team at the Wilmot Cancer Institute including hematology and oncology, radiation oncology, hematopathology, dermatology, neurology, nursing, advanced practice providers, social work and members of the clinical trials office.

I am actively engaged in clinical trials research and feel that this is an important component of care for lymphoma patients.

My lymphoma practice team includes Taylor Fox, NP and Abir Hines, RN. My team for autologous stem cell transplantation and CAR T-cells includes Anna Morrison, RN.

Professional Background

Dr. Reagan is an Assistant Professor of Medicine at the Wilmot Cancer Institute.

Dr. Reagan received his medical degree from Upstate Medical University in Syracuse, NY. He completed his internship and residency at the University of Virginia. He then served as a chief resident at the University of Virginia. He completed his fellowship in hematology at the Wilmot Cancer Institute at the University of Rochester Medical Center.

He started his faculty appointment at the Wilmot Cancer Institute in July 2015.



  • Internal Medicine - American Board of Internal Medicine


MD | SUNY Upstate College of Health Professions

Post-doctoral Training & Residency

07/01/2013 - 06/30/2015
Fellowship in Hematology & Oncology at University of Rochester Medical Center

07/01/2012 - 07/01/2013
Residency in Internal Medicine at University of Virginia-Radiology GME

07/01/2010 - 07/01/2012
Residency in Internal Medicine at University of Virginia-Radiology GME

07/01/2009 - 07/01/2010
Internship in Internal Medicine at University of Virginia-Radiology GME

VIEW ALL expand_more


Lymphoma Research Foundation Clinical Research Mentoring Program

American Society of Hematology Clinical Research Training Institute

John and Carol Bennett Travel Fellowship Award
Sponsor: John and Carol Bennett
Location: Wilmot Cancer Institute

Alpha Omega Alpha, Upstate Medical University
Sponsor: Upstate Medical University

Phi Beta Kappa, St. Lawrence University
Sponsor: St. Lawrence University

Academic All American, Football, St. Lawrence University
Sponsor: St. Lawrence University

Beta Beta Beta, Biological Honor Society, St. Lawrence University
Sponsor: St. Lawrence University

VIEW ALL expand_more

Clinical Trials

Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Lead Researcher: Patrick M Reagan

The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.

View Study Details

ILYM-15080, KTE-C19-102: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (MCL) (ZUMA-2)

Lead Researcher: Patrick M Reagan

The primary objective of the study is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (MCL)

View Study Details

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade

Lead Researcher: Patrick M Reagan

The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.

View Study Details

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients (EA4181)

Lead Researcher: Patrick M Reagan

This phase II trial compares three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating patients with newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This study is being done to find out if one the drug combinations of bendamustine, rituximab, high dose cytarabine, and acalabrutinib is better or worse than the usual approach for mantle cell lymphoma.

View Study Details


Journal Articles

Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. "Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma." Haematologica.. 2022 Jul 14; Epub 2022 Jul 14.

Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI. "Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study." The Lancet. Oncology.. 2022 Jul 12; Epub 2022 Jul 12.

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM. "Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2022 Jun 4; :JCO2102370. Epub 2022 Jun 04.